about
Maternal autoimmune diseases and immunologically induced embryonic and fetoplacental damageMaternal morbidity associated with multiple repeat cesarean deliveriesIs Anti-Müllerian Hormone Associated With Fecundability? Findings From the EAGeR TrialWork-up of stillbirth: a review of the evidenceMaternal Marijuana Use, Adverse Pregnancy Outcomes and Neonatal Morbidity.Route of Delivery in Women With Stillbirth: Results From the Stillbirth Collaborative Research Network.Stillbirth, hypertensive disorders of pregnancy, and placental pathology.Characteristics of a global classification system for perinatal deaths: a Delphi consensus studyInvited commentary: maternal stress and stillbirth: another piece of the puzzle.Maternal coagulation disorders and postpartum hemorrhage.Linking maternal platelet counts with neonatal platelet counts and outcomes using the data repositories of a multihospital health care system.Synthesis of sFlt-1 by platelet-monocyte aggregates contributes to the pathogenesis of preeclampsia.Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial.Prothrombin gene G20210A mutation and obstetric complications.Evaluation and Management of Women and Newborns With a Maternal Diagnosis of Chorioamnionitis: Summary of a Workshop.Karyotype versus microarray testing for genetic abnormalities after stillbirth.Outcomes of expectantly managed pregnancies with multiple gestations and preterm premature rupture of membranes prior to 26 weeksThe effect of a very short interpregnancy interval and pregnancy outcomes following a previous pregnancy loss.Fetal growth and risk of stillbirth: a population-based case-control study.The association of stillbirth with depressive symptoms 6-36 months post-delivery.A description of the methods of the Nulliparous Pregnancy Outcomes Study: monitoring mothers-to-be (nuMoM2b).NuMoM2b Sleep-Disordered Breathing study: objectives and methods.Bile acids in a multicenter, population-based case-control study of stillbirth.Preconception low dose aspirin and time to pregnancy: findings from the effects of aspirin in gestation and reproduction randomized trial.Autoimmune disease in pregnancy: systemic lupus erythematosus and antiphospholipid syndrome.The Influence of Risk Perceptions and Efficacy Beliefs on Leisure-Time Physical Activity During Pregnancy.Sex ratio following preconception low-dose aspirin in women with prior pregnancy lossEvaluation of an international educational programme for health care professionals on best practice in the management of a perinatal death: IMproving Perinatal mortality Review and Outcomes Via Education (IMPROVE)Trends in Stillbirth by Gestational Age in the United States, 2006-2012Expanded findings from a randomized controlled trial of preconception low-dose aspirin and pregnancy loss.An algorithm for the estimation of gestational age at the time of fetal death.Preconception counseling for women with thrombophilia.Pregnancy as a Window to Future Cardiovascular Health: Design and Implementation of the nuMoM2b Heart Health Study.Fetal death.Complications and Safety of Preconception Low-Dose Aspirin Among Women With Prior Pregnancy Losses.Ultrasound Measurement of the Fetal Adrenal Gland as a Predictor of Spontaneous Preterm Birth.A population-based case-control study of stillbirth: the relationship of significant life events to the racial disparity for African Americans.Antimüllerian hormone and pregnancy loss from the Effects of Aspirin in Gestation and Reproduction trial.Do antiphospholipid antibodies cause preeclampsia and HELLP syndrome?Stillbirth Collaborative Research Network: design, methods and recruitment experience.
P50
Q28169065-5A51CB94-7945-4D63-B20B-83041ED391B8Q28243198-619FA8CC-DCE9-4BA9-B04A-80B276C1F70EQ28383121-0002E3A2-6DBC-4F9F-9FB5-C67131318CF8Q28389394-A7CAC5ED-4031-4F72-80AD-1CC12C1D6C0FQ30252214-CD9CA884-351E-4B3B-B81F-041DB8C0581EQ30252888-C1836741-14B0-4191-9D82-4C19C3389A6DQ30276543-D11F8466-13D6-4396-BF4C-689B619289FFQ30382280-0F0C0552-9917-493A-94FB-ECA31F283F2CQ33354994-CB24F9A7-800D-4DF2-B0F6-4BADC8842F2BQ33388198-B01D97D3-8D46-4A6A-BB24-525406231E02Q33395204-60D4FD7D-14C9-43D2-B5B2-250F70D40E2AQ33698336-51523E30-900D-4A3E-8DD9-86C9C30E6E3AQ34274204-124A0F38-7B8F-4C5E-8307-9F5C4E1A3506Q34311734-CE2CCBD4-3FAE-4A86-9E9E-06B735B77A53Q34675647-6632B0A6-36A3-488D-B2A4-0B62F4A57AC7Q34966044-0556020D-826B-4B13-99C3-73046E41BD27Q35033746-E7978FC1-2634-4D61-8FB6-1D7B2066EE78Q35137509-A0F0F1D7-2458-45D8-9764-D7F6BBD4AAAEQ35154809-9E85F858-1756-4BF0-82CB-8D9D496888FFQ35212338-526D846C-7FEC-46C4-9003-FB50A96A24B9Q35287430-20D11D7E-6778-4293-AF5D-B0797FAC81CCQ35541483-A8D3B9BB-275F-4C59-ADF3-E76BBD89426BQ35551116-3CDB3187-290E-46EB-A6B8-2918E3C6D81AQ35578239-52CCC285-6BA6-4B9C-A918-D89A0F66DFEFQ35807593-ED89A12C-F622-430B-9009-76EB00BD7BC8Q35830312-54181B10-7702-4A42-A252-AD2A784D2653Q36106043-04A0EC5F-575F-4493-91C0-7BF937D12E63Q36204118-528E6937-8862-4789-871E-E03C46E9E348Q36347712-49080915-43B0-466F-B0A8-039C5F9E6812Q36585168-A3D93E54-07B6-467E-8A54-1DB648778CD7Q36587174-BE4CFF4D-667D-4BB2-8A51-46C8D02E5648Q36643510-F914D7A6-F8A3-46FA-958C-A95C05B02FC1Q36663565-4E83EC87-CDF7-4E3E-A51D-017B6F6DB2E3Q36696213-BEB1E815-F4EC-4734-8C87-307DEE698819Q36723118-B26D53C2-F70D-4EB7-ADCB-4ADEE1834633Q36723123-8034500A-188C-4EE0-A1A2-DB27F14FBC5AQ36762027-83FD11B4-D647-4C19-A7F9-B7ECCBE239FDQ36768031-D4FD6F1A-9A45-48BF-A819-4CAE60177AFAQ36832533-7C2C976F-0F3B-4D28-97F6-076F71B9F8C6Q36880470-31A488B9-FDD7-4201-A9BD-C533EC9C7423
P50
name
Robert M Silver
@ast
Robert M Silver
@en
Robert M Silver
@es
Robert M Silver
@nl
type
label
Robert M Silver
@ast
Robert M Silver
@en
Robert M Silver
@es
Robert M Silver
@nl
prefLabel
Robert M Silver
@ast
Robert M Silver
@en
Robert M Silver
@es
Robert M Silver
@nl